KASMEJ
Kastamonu Medical Journal

Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

eISSN: 2757-9336
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Coagulation parameters and prognosis analysis in COVID-19 patients
Abstract
Aims: There are many factors that affect morbidity and mortality in COVID-19. Coagulopathy is thought to be one of the important mechanisms in COVID-19 mortality. In this study, it was aimed to investigate coagulation factors and their relationship with prognosis in COVID-19.
Methods: Patients diagnosed with COVID-19 were retrospectively reviewed in our hospital. The patients' demographic data, laboratory data on admission to the hospital, intensive care admissions, and surveillance were recorded. Patients were divided into two groups; Group 1 is non-critical patients followed up in the clinic, Group 2 is critical patients who need treatment in the intensive care unit.
Results: 403 patients followed up for COVID-19 were analyzed. It was determined that the average age of the patients in Group 1 was statistically significantly lower than those in Group 2. (1: 45.28 ± 15.31 vs. 2: 60.15 ± 15.72, respectively, p <0.001). It was observed that the rates of HT, DM, CHD, and COPD in Group 2 were statistically significantly higher than Group 1 (p <0.05). While APTT values were similar in both groups, D-Dimer values were significantly higher in Group 2. As QSOFA, SIC, DIC, and coagulation marker scores increased, the percentage of patients with death increased significantly (p <0.05). Age, HT, COPD, PT, and high fibrinogen levels were found to increase the mortality risk rates statistically (p <0.05).
Conclusion: It was determined that the most important factors determining mortality in COVID-19 are COPD and HT. APTT and D-dimer values were not found to be a prognostic factor in terms of mortality. However, PT, fibrinogen, and age are poor prognostic factors and can be used to predict mortality requiring intensive care.

Keywords : COVID-19, coagulopathy, prognosis, mortality.

Download Article


1. Long B, Carius BM, Chavez S, et al. Clinical update on COVID-19 for the emergency clinician: presentation and evaluation. Am J Emerg Med. 2022;54:46-57.
2. Voicu S, Delrue M, Chousterman BG, et al. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications. Eur Rev Med Pharmacol Sci. 2020;24:9161-9168.
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
5. Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021;47:100761.
6. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
8. Girgin S, Aksun M, T&uuml;zen AS, et al. Effects of comorbidities associated with COVID-19 cases in intensive care unit on mortality and disease progression. Eur Rev Med Pharmacol Sci. 2023;27(8):3753-3765.
9. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
10. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
11. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145-148.
12. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombol. 2021;1107-1110.
13. Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19 coagulopathy in caucasian patients. Br J Haematol. 2020;189(6):1044-1049.
14. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.
15. Yu M, Nardella A, Pechet L. Screening tests of disseminated intravascular coagulation: Guidelines for rapid and specific laboratory diagnosis. Crit Care Med. 2000;28(6):1777-1780.
16. Taylor F, Toh C-H, Hoots K, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(11):1327-1330.
17. Chandrashekar V. DIC score: statistical relationship with PT, APTT, and Simplified scoring systems with combinations of PT and APTT. ISRN Hematol. 2012;1-4.
18. Papageorgiou C, Jourdi G, Adjambri E, et al. Disseminated intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic strategies. Clin Appl Thromb. 2018;24(9):8-28.
19. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11(4):761-767.
20. Hu Y, Wang YD. How I treat disseminated intravascular coagulation. Zhonghua Xue Ye Xue Za Zhi. 2017;38(5):371-374.
21. Vidali S, Morosetti D, Granai AV, Legramante JM, Buonomo OC, Argir&ograve; R. Splenoportal-mesenteric axis thrombosis and splenic artery occlusion as initial presentations of COVID-19 disease. Eur Rev Med Pharmacol Sci. 2021;25(3):1680-1683.
22. Dwiputra Hernugrahanto K, Novembri Utomo D, Hariman H, et al. Thromboembolic involvement and its possible pathogenesis in COVID-19 mortality: lesson from post-mortem reports. Eur Rev Med Pharmacol Sci. 2021;25(3):1670-1679.
23. Taşkın &Ouml;, Soylu VG, Demir U, et al. Retrospective evaluation of critical geriatric and adult COVID-19 patients. Kastamonu Med J. 2021;1(3): 71-74.
24. Dereli N, Babayiğit M, Ko&ccedil; F, et al. Type-H, and Type-L COVID-19: are they different subtypes or the same? Eur Rev Med Pharmacol Sci. 2022;26(9):3367-3373.
25. Demir U, Soylu VG, Taşkın &Ouml;, Yılmaz A. Change of critical COVID-19 disease in time. Kastamonu Med J. 2022;2(2): 35-38.
26. Dereli N, Babayigit M, Ko&ccedil; F, et al.The relationship between inflammatory parameters and mortality in COVID-19 patients treated in the intensive care unit.Eastern J Med. 2022;27(1):146-154
27. Venkata C, Kashyap R, Christopher Farmer J, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. J Intensive Care. 2013;1(1):1-10.
28. McGonagle D, O&rsquo;Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2(7):437-445.
Article available in :
Volume 3, Issue 4, 2023
Page : 198-203
https://doi.org/10.51271/KMJ-0126
Article Information
Received : 13 Eyl 2023
Accepted : 31 Eki 2023
Published : 17 Ara 2023
Corresponding Author :

Filiz Koç: Department of Infection Diseases and Clinical Microbiology

[email protected]
Citation : Koç F, Babayiğit M. Coagulation parameters and prognosis in COVID-19 patients. Kastamonu Med J. 2023;3(4):198-203.

Read: 36
Cited: 0
Download : 495
_Footer